ATHA Oct 2024 7.500 put
| Previous close | 4.3000 |
| Open | N/A |
| Bid | 4.2000 |
| Ask | 8.5000 |
| Strike | 7.50 |
| Expiry date | 2024-10-18 |
| Day's range | 4.3000 - 4.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 270 |
Simply Wall St.retail investors who own 35% along with institutions invested in Athira Pharma, Inc. (NASDAQ:ATHA) saw increase in their holdings value last week
Key Insights The considerable ownership by retail investors in Athira Pharma indicates that they collectively have a...
GlobeNewswireAthira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint, the Global Statistical Test, designed to measure overall impact on disease Webinar event on Tuesday, June 18th at 11:30 a.m. ET BOTHELL, Wash., June 12, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clin
- GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dos
